Challenges in the Screening and Management of Osteoporosis

References

1. ↵
   1. Looker AC,
   2. Melton LJ 3rd.,
   3. Harris TB,
   4. Borrud LG,
   5. Shepherd JA

   Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res. 2010;25(1):64-71.

   OpenUrlCrossRefPubMed
2. ↵
   1. Office of the Surgeon General

   Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services; 2004:1-404
3. ↵
   1. Miyamoto RG,
   2. Kaplan KM,
   3. Levine BR,
   4. Egol KA,
   5. Zuckerman JD

   Surgical management of hip fractures: an evidence-based review of the literature. I: femoral neck fractures. J Am Acad Orthop Surg. 2008;16(10):596-607.

   OpenUrlCrossRefPubMed
4. ↵
   1. Kado DM,
   2. Browner WS,
   3. Palmero L,
   4. Nevitt MC,
   5. Genant HK,
   6. Cummings SR

   Study of osteoporotic fractures research group. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med. 1999;159(11):1215-1220.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Burge R,
   2. Dawson-Hughes B,
   3. Solomon DH,
   4. Wong JB,
   5. King A,
   6. Tosteson A

   Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Black DM,
   2. Cummings SR,
   3. Karpf DB, et al.

   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-1541.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. U.S. Preventive Services Task Force

   Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356-364.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Altkorn D,
   2. Cifu AS

   Screening for osteoporosis. JAMA. 2015;313(14):1467-1468.

   OpenUrl
9. ↵
   1. Dell R,
   2. Greene D

   Is osteoporosis disease management cost effective? Curr Osteoporos Rep. 2010;8(1):49-55.

   OpenUrlCrossRefPubMed
10. ↵
    1. Cosman F,
    2. de Beur SJ,
    3. LeBoff MS, et al., National Osteoporosis Foundation

    Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381.

    OpenUrlCrossRefPubMed
11. ↵
    Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25-54; quiz 55-56.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Wells GA,
    2. Cranney A,
    3. Peterson J, et al.

    Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155.
13. ↵
    1. Black DM,
    2. Schwartz AV,
    3. Ensrud KE, et al., FLEX Research Group

    Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Downey TW,
    2. Foltz SH,
    3. Boccuzzi SJ,
    4. Omar MA,
    5. Kahler KH

    Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006;99(6):570-575.

    OpenUrlCrossRefPubMedWeb of Science
15. 1. Tomková S,
    2. Telepková D,
    3. Vanuga P, et al.

    Therapeutic adherence to osteoporosis treatment. Int J Clin Pharmacol Ther. 2014;52(8):663-668.

    OpenUrl
16. ↵
    1. Chodick G,
    2. Moser SS,
    3. Goldshtein I

    Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):359-370.

    OpenUrl
17. ↵
    1. Ringe JD,
    2. Doherty JG

    Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int. 2010;30(7):863-869.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Winzenberg T,
    2. Jones G

    When do bisphosphonates make the most sense? J Fam Pract. 2011;60(1):18-28.

    OpenUrlPubMed
19. ↵
    1. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws,
    2. American Association of Oral and Maxillofacial Surgeons

    American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369-376.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Park-Wyllie LY,
    2. Mamdani MM,
    3. Juurlink DN, et al.

    Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783-789.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. American Geriatrics Society Workgroup on Vitamin D Supplementation in Older Adults

    Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc. 2014;62(1):147-152.

    OpenUrlCrossRefPubMed
22. ↵
    1. American Geriatrics Society 2015 Beers Criteria Update Expert Panel

    American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246.

    OpenUrlCrossRefPubMed
23. ↵
    1. Bukata SV,
    2. DiGiovanni BF,
    3. Friedman SM, et al.

    A guide to improving the care of patients with fragility fractures. Geriatr Orthop Surg Rehabil. 2011;2(1):5-37.

    OpenUrlFREE Full Text
24. ↵
    1. Nakayama A,
    2. Major G,
    3. Holliday E,
    4. Attia J,
    5. Bogduk N

    Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016;27(3):873-879.

    OpenUrl